Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases

Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases

Hepatitis B virus (HBV) is a DNA virus transmitted predominantly by sexual contact or percutaneous exposure. HBV infection is by far the most common chronic viral infection affecting the liver in the world, and a leading cause of cirrhosis and hepatocellular carcinoma. Reactivation of HBV replicatio...

Full description

Bibliographic Details
Main Authors:	C. Bazzani, M. Frassi, P. Airò, S. Zingarelli, M. Scarsi, M. Puoti
Format:	Article
Language:	English
Published:	PAGEPress Publications 2011-09-01
Series:	Reumatismo
Online Access:	http://www.reumatismo.org/index.php/reuma/article/view/350

Similar Items

Assessment of the vaccination status in rheumatic disease patients treated with disease-modifying antirheumatic drugs
by: Luisa Brites, et al.
Published: (2019-07-01)

Lipid profiles in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs
by: Anna Filipowicz-Sosnowska, et al.
Published: (2014-06-01)

Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
by: Abhishek Zanwar, et al.
Published: (2017-01-01)

Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents
by: Chin, K., et al.
Published: (2022)

Chronic pain and central sensitization in immuno-inflammatory rheumatic diseases: pathogenesis, clinical manifestations, the possibility of using targeted disease modifying antirheumatic drugs
by: A. E. Karateev, et al.
Published: (2019-05-01)

PNEUMOCYSTIC PNEUMONIA IN RHEUMATIC DISEASES: CURRENT ISSUES IN PROPHYLAXIS
by: M. S. Eliseev
Published: (2018-01-01)

VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs
by: David Schub, et al.
Published: (2018-11-01)

PNEUMOCYSTIC PNEUMONIA IN RHEUMATIC DISEASES: CURRENT ISSUES IN PROPHYLAXIS
by: B. S. Belov, et al.
Published: (2018-01-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Prophylaxis of Rheumatic Fever/Rheumatic Heart Disease–Penicillin or Azithromycin, Who Wins?
by: Arati Lalchandani, et al.
Published: (2021-01-01)

Disease-modifying antirheumatic drugs – Old and new: A brief overview
by: Vidya Divakar Baliga, et al.
Published: (2019-01-01)

Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy
by: Anna Czekalska, et al.
Published: (2019-08-01)

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
by: Kemper Alex R, et al.
Published: (2012-03-01)

Gold Finger: Metal Jewellery as a Disease Modifying Antirheumatic Therapy!
by: T. Hlaing, et al.
Published: (2009-01-01)

Disease-Modifying Antirheumatic Diets: The New Treatment Modalities for Rheumatoid Arthritis
by: Shweta Khanna, et al.
Published: (2018-07-01)

Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease‐Modifying Antirheumatic Drugs
by: Gulsen Ozen, et al.
Published: (2019-09-01)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
by: Matt Stevenson, et al.
Published: (2016-04-01)

Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs
by: Salmi Abdul Razak, et al.
Published: (2020-11-01)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
by: Xia Y, et al.
Published: (2016-05-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
by: Alicja Góralczyk, et al.
Published: (2020-07-01)

A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept
by: Zeremski Vanja, et al.
Published: (2016-01-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Adherence to secondary prophylaxis and disease recurrence in 536 Brazilian children with rheumatic fever
by: de Oliveira Sheila KF, et al.
Published: (2010-07-01)

Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drugs
by: Ajinkya Pawar, et al.
Published: (2021-08-01)

Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study
by: Johan Askling, et al.
Published: (2020-08-01)

Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence.
by: M van Heuckelum, et al.
Published: (2019-01-01)

Lung lesion caused by the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
by: Yuriy Vladimirovich Murav'ev, et al.
Published: (2010-12-01)

Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine
by: Claire I. Daïen, et al.
Published: (2014-01-01)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan
by: Emma Sullivan, et al.
Published: (2020-05-01)

EFFECTS OF SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS, BIOLOGICAL AGENTS, AND PSYCHOPHARMACOTHERAPY ON THE MENTAL DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin, et al.
Published: (2017-09-01)

Adherence to secondary prophylaxis for rheumatic heart disease is underestimated by register data.
by: Jessica Langloh de Dassel, et al.
Published: (2017-01-01)

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
by: van Heuckelum M, et al.
Published: (2019-07-01)

Adherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies
by: Canfield, S., et al.
Published: (2021)

Benzathine Penicillin Prophylaxis in Children with Rheumatic Fever (RF)/ Rheumatic Heart Disease (RHD): A Study of Compliance
by: Radha G. Ghildiyal, et al.
Published: (2010-04-01)

Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial
by: Jon T. Giles, et al.
Published: (2021-06-01)

Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
by: Sofia Ramiro, et al.
Published: (2020-05-01)

Drogas Modificadoras de la Artritis Reumatoide (DMAR) Disease Modifying Antirheumatic Drugs (DMARD)
by: José Francisco Díaz-Coto, et al.
Published: (2011-02-01)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
by: Ronald van Vollenhoven, et al.
Published: (2018-10-01)

Data from the Romanian Registry of Rheumatic Diseases for patients with psoriatic arthritis treated with biologic disease-modifying anti-rheumatic drugs during 2019
by: Andra Balanescu, et al.
Published: (2020-06-01)